Rivastigmine Sandoz 13
As listed in the register: Rivastigmine Sandoz 13,3 mg/24 uur, pleisters voor transdermaal gebruik
13,3 mg · pleister voor transdermaal gebruik
- Prescription only
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Rivastigmine
- Made by
- Sandoz B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Rivastigmine). It describes the substance, not this exact product.
Although the precise mechanism of action of rivastigmine is unknown, it is thought to exert its therapeutic effect by enhancing cholinergic function.
This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase.
Rivastigmine is extensively metabolized primarily via cholinesterase-mediated hydrolysis to the decarbamylated metabolite NAP226-90.
Less than 1% of the administered dose is excreted in the feces.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-11-14
Safety of the active substance
From the US prescribing label for the same active substance (Rivastigmine). It describes the substance, not this exact product.
- Known hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the formulation.
- ( 4 ) History of application-site reactions with rivastigmine transdermal system suggestive of allergic contact dermatitis.
- ( 4, 6.2 ) Rivastigmine transdermal system is contraindicated in patients with: known hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the formulation [see Description ( 11 )]. previous history of application-site reactions with rivastigmine transdermal system suggestive of allergic contact dermatitis [see Warnings and Precautions ( 5.3 )].
- Isolated cases of generalized skin reactions have been described in postmarketing experience [see Adverse Reactions ( 6.2 )].
Most common adverse reactions (less than 5% and higher than with placebo): Nausea, vomiting, and diarrhea.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
CanadaNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Sandoz B.V. |
|---|---|
| Active substance | Rivastigmine |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Strength | 13,3 mg |
| Form | pleister voor transdermaal gebruik |
| Classification | N06DA03 · Pain, sleep, mood, epilepsy and the brain |
| Route | transdermaal gebruik |
| Dispensing (as stated by the register) | Uitsluitend recept |
| Name in the register | Rivastigmine Sandoz 13,3 mg/24 uur, pleisters voor transdermaal gebruik |
| RVG | 115384 |
Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician
Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.